Short Interest in Threshold Pharmaceuticals Inc. (THLD) Increases By 64.3%
Threshold Pharmaceuticals Inc. (NASDAQ:THLD) saw a significant growth in short interest in September. As of September 15th, there was short interest totalling 1,656,030 shares, a growth of 64.3% from the August 31st total of 1,008,063 shares. Approximately 2.5% of the company’s shares are short sold. Based on an average trading volume of 5,902,208 shares, the days-to-cover ratio is presently 0.3 days.
Large investors have recently bought and sold shares of the company. Oxford Asset Management increased its stake in Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 178,602 shares in the last quarter. Paloma Partners Management Co bought a new stake in Threshold Pharmaceuticals during the second quarter valued at about $152,000. Renaissance Technologies LLC increased its stake in Threshold Pharmaceuticals by 55.5% in the first quarter. Renaissance Technologies LLC now owns 1,016,764 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 363,100 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock valued at $1,610,000 after buying an additional 500,000 shares in the last quarter. Finally, Deerfield Management Co. bought a new stake in Threshold Pharmaceuticals during the second quarter valued at about $1,641,000. Hedge funds and other institutional investors own 28.22% of the company’s stock.
THLD has been the subject of several recent analyst reports. William Blair restated an “outperform” rating on shares of Threshold Pharmaceuticals in a report on Monday. S&P Equity Research lowered their price target on Threshold Pharmaceuticals from $0.67 to $0.52 in a report on Friday, September 30th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.26.
Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.5531 on Wednesday. Threshold Pharmaceuticals has a 12-month low of $0.21 and a 12-month high of $4.44. The company’s 50 day moving average price is $1.05 and its 200-day moving average price is $0.62. The company has a market capitalization of $39.55 million, a P/E ratio of 0.9343 and a beta of 3.98.
Threshold Pharmaceuticals (NASDAQ:THLD) last posted its earnings results on Monday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Equities analysts forecast that Threshold Pharmaceuticals will post ($0.38) earnings per share for the current fiscal year.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Stock Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.